News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarillo Biosciences (AMAR) Signs Deal with CytoPharm of Taiwan


3/25/2008 1:28:38 PM

March 25, 2008 -- Amarillo Biosciences, Inc. (OTCBB: AMAR) has entered a second license and supply agreement with CytoPharm, Inc. of Taiwan for Amarillo Biosciences’ low-dose interferon. Under this agreement, CytoPharma will conduct tests to support the use of low-dose interferon in animals (swine, poultry, cattle) to treat or prevent animal diseases. CytoPharm will seek approval of the drug in Taiwan and China. CytoPharm is already conducting a Phase II clinical trial to test whether low-dose interferon can prevent relapse in hepatitis C patients. More details...

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES